Vertex Pharmaceuticals, Inc.

Randal Byrn

Mark Willem Ledeboer

Steven Jones

Francesco Gerald Salituro

Tiansheng Wang

Paul S Charifson

Francois Maltais

Luc J Farmer

Emanuele Perola

Huai Gao

John J Court

Chao Lin

Upul Keerthi Bandarage

Hongbo Deng

Randy Scott Bethiel

John P Duffy

Brian Ledford

Wenxin Gu

Joseph M Kennedy

Michael P Clark

M Woods Wannamaker

Ioana Davies

Ursula A Germann

Dylan H Jacobs

Yi Zhou

Min Jiang

Ann Dak-Yee Kwong

Lola M Reid

Ann Kwong

Douglas John Bartels

Hamilton Barlow Bennett

Joshua Robert Leeman

Ales Medek

Valdas Jurkauskas

Yi Shi

Michael Waldo

Praveen Mudunuri

Ioana Drutu

Kwame Wiredu Nti-Addae

Sarah Robertson

Mohammed Asmal

Simon Adam O'Neil

John Gregg Van Alsten

Wanjung Tsai

Dainius Macikenas

Sarah Marie Robertson

Woods M Wannamaker

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Inhibitors of influenza viruses replication

The present invention relates to influenza A virus variants, particularly variants that are resistant to a polymerase inhibitors. Also provided are methods and compositions related to the influenza A virus variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.

Influenza A virus variants

Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).&#xbd;HO, Form F of HCl salt of Compound (1).3HO, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.

The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.

Method useful for HCV RNA898 infection

Compositions and methods useful for HCV infection

Growing community of inventors

Wayland, MA, United States of America

Randal Byrn